Heart Health9-Apolipoprotein Blood Panel Outperforms Standard Cholesterol Tests for Heart Attack Risk
Researchers analyzed blood samples from nearly 12,000 post-heart-attack patients enrolled in the ODYSSEY OUTCOMES trial. They compared a 9-protein apolipoprotein panel measured by mass spectrometry against the standard cholesterol test for predicting future heart attacks, strokes, and death. The apolipoprotein panel substantially outperformed the conventional lipid panel. Crucially, patients identified as high-risk by the apolipoprotein panel also showed the greatest benefit from alirocumab (Praluent), a PCSK9 inhibitor. This suggests the panel could serve a dual role: identifying who is at elevated residual risk despite statin therapy, and pinpointing who will respond best to expensive add-on treatments — a potential breakthrough for precision cardiovascular medicine.
